RSS-Feed abonnieren
PDF herunterladen
DOI: 10.3413/Nukmed-0688-14-07
Therapie des Patienten mit Radioiod-refraktärem, differenziertem Schilddrüsenkarzinom[*]
Ein KonsensusstatementPublikationsverlauf
received:
29. Juli 2014
accepted in revised form:
11. November 2014
Publikationsdatum:
28. Dezember 2017 (online)
Zusammenfassung
Für die Therapie eines Patienten mit Radioiod- refraktärem, differenziertem Schilddrüsenkarzinom sind zurzeit keine klaren Standards definiert. Mit dem kürzlich in dieser Indikation zugelassenen Multitarget-Kinase - inhibitor Sorafenib ist die therapeutische Landschaft erweitert worden.
Ein interdisziplinäres Experten-Panel bestehend aus endokrinen Chirurgen, internistischen Onkologen und Nuklearmedizinern hat Empfehlungen für die Definition und das Vorgehen bei Radioiod-refraktären Karzinomen erarbeitet.
Summary
There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The therapeutic options for this indication have expanded with the recently approved multiple kinase inhibitor sorafenib.
Recommendations for the definition and the management of iodine refractory patients were worked up by an interdisciplinary expert panel, consisting of endocrine surgeons, medical oncologists and nuclear medicine specialists.
* Dieses Konsens-Papier entstand im Rahmen der Master-Arbeit von Christina Lindner an der IMC FH Krems, wobei der praktische Teil bei Bayer Austria GmbH absolviert wurde.
-
Literatur
- 1 Brose MS, Frenette CT, Keefe SM. et al. Management of sorafenib-related adverse events. Semin Oncol 2014; 41 (Suppl 2) S1-S16.
- 2 Brose MS, Nutting CM, Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer. Lancet 2014; 384: 319-328.
- 3 Brose MS, Nutting CM, Sherman SI. et al. Rationale and design of decision. BMC cancer 2011; 11: 349.
- 4 Cabanillas ME, Waguespack SG, Bronstein Y. et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer. J Clin Endocr Metab 2010; 95: 2588-2595.
- 5 Chen L, Shen Y, Luo Q. et al. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 2011; 21: 119-124.
- 6 Deandreis D, Al Ghuzlan A, Leboulleux S. et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. Endocr Relat Cancer 2011; 18: 159-169.
- 7 Durante C, Haddy N, Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 2892-2899.
- 8 Escudier B, Eisen T, Stadler WM. et al. Sorafenib for treatment of renal cell carcinoma. J Clin Oncol 2009; 27: 3312-3318.
- 9 Ferlay J, Shin HR, Bray F. et al. Estimates of worldwide burden of cancer in 2008. Int J Cancer 2010; 127: 2893-2917.
- 10 Flaherty KT, Infante JR, Daud A. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
- 11 Gerlinger M, Rowan AJ, Horswell S. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
- 12 Giovanella L, Trimboli P, Verburg FA. et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2013; 40: 874-880.
- 13 Helal BO, Merlet P, Toubert ME. et al. Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy. J Nucl Med 2001; 42: 1464-1469.
- 14 Ho AL, Grewal RK, Leboeuf R. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013; 368: 623-632.
- 15 Hoftijzer H, Heemstra KA, Morreau H. et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161: 923-931.
- 16 Iten F, Muller B, Schindler C. et al. 90Yttrium-DOTA-TOC response is associated with survival benefit in iodine-refractory thyroid cancer. Cancer 2009; 115: 2052-2062.
- 17 Ito Y, Miyauchi A, Ito M. et al. Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy. Endocr J 2014; 61: 821-824.
- 18 Juweid ME, Cheson BD. Positron-emission toography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507.
- 19 Kohlfuerst S, Igerc I, Gallowitsch HJ. et al. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?. Thyroid 2006; 16: 1113-1119.
- 20 Llovet JM, Ricci S, Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
- 21 Miyauchi A, Kudo T, Miya A. et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 2011; 21: 707-716.
- 22 Nikiforov YE. Thyroid carcinoma. Mod Pathol 2008; 21 (Suppl 2) S37-S43.
- 23 Pacini F, Castagna MG, Brilli L. et al. Thyroid cancer. Ann Oncol 2012; 23 (Suppl 7) vii110-vii119.
- 24 Regalbuto C, Frasca F, Pellegriti G. et al. Update on thyroid cancer treatment. Future Oncol 2012; 8: 1331-1348.
- 25 Robbins RJ, Hill RH, Wang W. et al. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 2000; 10: 177-183.
- 26 Robbins RJ, Wan Q, Grewal RK. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91: 498-505.
- 27 Schlumberger M, Brose M, Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014; 2: 356-358.
- 28 Shimaoka K, Schoenfeld DA, DeWys WD. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56: 2155-2160.
- 29 Spano JP, Vano Y, Vignot S. et al. GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. Med Oncol 2012; 29: 1421-1428.
- 30 Summary of Product Characteristics. Doxorubicin 2 mg/ml concentrate for solution for infusion. 2014 www.medicines.org.uk/emc/medicine/25946/spc
- 31 Waldherr C, Schumacher T, Pless M. et al. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octreotide. Nucl Med Commun 2001; 22: 673-678.